Published in Br J Clin Pharmacol on January 01, 1984
Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br J Clin Pharmacol (1985) 1.06
Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol (1991) 0.87
Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man. Br J Clin Pharmacol (1985) 0.86
The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition. Br J Clin Pharmacol (1985) 0.84
Lack of effect of atenolol on the pharmacokinetics of theophylline. Br J Clin Pharmacol (1988) 0.79
The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. Br J Clin Pharmacol (1988) 0.76
Lack of effect of atenolol and nadolol on the metabolism of theophylline. Br J Clin Pharmacol (1990) 0.75
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials. Lancet (1981) 2.01
The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther (1972) 1.88
Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol (1979) 1.79
Lidocaine plasma protein binding. Clin Pharmacol Ther (1980) 1.74
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med (1980) 1.42
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med (1980) 1.35
Adrenergic beta receptor blockade: hemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther (1981) 1.30
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J (1976) 1.20
Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther (1983) 1.14
Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1976) 1.11
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. J Pharmacol Exp Ther (1973) 1.10
A comparison of the acute haemodynamic effects of propranolol and pindolol at rest and during supine exercise in man. Clin Sci (Lond) (1980) 1.08
A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med (1983) 1.06
Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol (1977) 1.04
Influence of long-term infusions on lidocaine kinetics. Clin Pharmacol Ther (1982) 1.01
Factors influencing serum protein binding of lidocaine in humans. Anesth Analg (1981) 0.99
The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J Pharmacol Exp Ther (1981) 0.98
On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction. Br J Clin Pharmacol (1982) 0.94
Interactions of drugs active at opiate receptors and drugs active at alpha 2-receptors on various test systems. Br J Pharmacol (1982) 0.90
Hepatic clearance of local anesthetics in man. J Pharmacokinet Biopharm (1977) 0.89
On the metabolism of lidocaine. II. The biotransformation of lidocaine. Acta Pharmacol Toxicol (Copenh) (1961) 0.89
Effect of the duration of infusion on the disposition of lidocaine in dogs. J Pharmacol Exp Ther (1977) 0.89
Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. Br Med J (Clin Res Ed) (1983) 0.89
On the metabolism of lidocaine. I. The properties of the enzyme system responsible for the oxidative metabolism of lidocaine. Acta Pharmacol Toxicol (Copenh) (1961) 0.87
Disopyramide and lignocaine. A comparison of cardiac effects using echocardiography. Br J Clin Pharmacol (1980) 0.86
Lidocaine-propranolol interactions. N Engl J Med (1981) 0.83
Effects of beta-adrenoceptor antagonists on central haemodynamics in essential hypertension. Br J Clin Pharmacol (1982) 0.82
Effects of propranolol and pindolol on plasma lignocaine clearance in man. Br J Clin Pharmacol (1982) 0.80
Dose-dependent pharmacokinetic behavior of lidocaine in the conscious dog. Res Commun Chem Pathol Pharmacol (1978) 0.78
Lidocaine uptake in isolated rat hepatocytes and effects of dl-propranolol. Toxicol Appl Pharmacol (1980) 0.78
Time-dependent kinetics of lignocaine in the isolated perfused rat liver. J Pharmacokinet Biopharm (1983) 0.77
Single arterial trunk arising from the aortic arch. Circulation (1980) 0.77
beta 2-Adrenoceptors in rat liver microcirculation. Clin Exp Pharmacol Physiol (1979) 0.77
Effects of dl-propranolol on lidocaine disposition in the perfused rat liver. Drug Metab Dispos (1982) 0.77
Pharmacokinetic aspects of some beta-adrenoceptor blocking drugs. Acta Med Scand Suppl (1982) 0.77
High mortality among recipients of bought living-unrelated donor kidneys. Lancet (1990) 4.25
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
The cause of hepatic accumulation of fructose 1-phosphate on fructose loading. Biochem J (1970) 2.71
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Dangers of intravenous fructose. Lancet (1972) 2.15
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther (2006) 1.58
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol (1982) 1.55
Lactate production in the perfused rat liver. Biochem J (1971) 1.54
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol (1982) 1.52
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth (1994) 1.46
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand (2010) 1.41
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Lactic acidosis revisited. Diabetes (1983) 1.36
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Intermittent claudication: factors determining outcome. Br Med J (1978) 1.33
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Letter: Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature (1975) 1.27
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol (1994) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet (1980) 1.18
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11
Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol (1967) 1.08
Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05